Q2 2025 Corvus Pharmaceuticals Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: $4.13 (-0.96%)

Transcript 10-Q8-K

Key Points

Positve

Corvus Pharmaceuticals Inc (CRVS) reported a significant increase in cash equivalents and marketable securities, totaling $74.4 million as of June 30, 2025, compared to $52 million at the end of 2024.
The company successfully exercised all remaining common stock warrants, resulting in cash proceeds of approximately $35.7 million.
Corvus Pharmaceuticals Inc (CRVS) is advancing the clinical development of socolitinib for atopic dermatitis, with promising data from phase 1 trials showing favorable safety and efficacy profiles.
The company plans to initiate a phase 2 clinical trial for socolitinib in atopic dermatitis, which will be an international, randomized, placebo-controlled, and double-blinded study.
Corvus Pharmaceuticals Inc (CRVS) has a robust pipeline with ongoing trials in various indications, including T cell lymphoma, APS autoimmune lymphoproliferative syndrome, and renal cell cancer.

Negative

Research and development expenses increased significantly to $7.9 million in Q2 2025 from $4.1 million in the same period in 2024, primarily due to higher clinical trial and manufacturing costs.
The net loss for Q2 2025 was $8 million, compared to a net loss of $4.3 million in Q2 2024.
The company recorded a non-cash loss of $400,000 related to Angel Pharmaceuticals, its partner in China.
Stock compensation expense increased to $1.3 million in Q2 2025 from $800,000 in Q2 2024.
The company faces challenges in pursuing multiple indications simultaneously due to financial constraints, despite having a plethora of opportunities.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRVS.OQ - Corvus Pharmaceuticals Inc
Q2 2025 Corvus Pharmaceuticals Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, everyone.

Thank you for standing by and welcome to the Corvis Pharmaceuticals 2nd quarter 2025 business update and financial results conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question and answer session, and instructions will follow at that time. It is now my pleasure to turn the call over to Zach Kubo of Real Chemistry. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good afternoon, everyone. Thanks for joining us for the Corvis

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.